Four projects granted funding for innovative research
Four researchers at KI will receive grants from Johnson & Johnson Innovation, committed up to the next 2–3 years. The purpose is to identify and support high quality, innovative research that has the potential to provide new healthcare solutions.
Strategic questions are centred on the development of novel therapeutic interventions, understanding disease biology and identification of novel biomarkers across multiple therapeutic areas.
In May 2015, Karolinska Institutet (KI) entered into a strategic alliance with Johnson & Johnson Innovation to accelerate research emerging from KI that has a transformative potential with respect to healthcare innovation.
The selected projects will receive funding, resources and advice from Janssen, the pharmaceutical companies of the Johnson & Johnson group:
- Sophie Erhardt, professor at the Department of Physiology and Pharmacology. Project: Investigation of a potential novel biomarker for treatment-resistant depression and suicide risk.
- Malin Flodström-Tullberg, professor at the Department of Medicine, Huddinge and Susanne Gabrielsson, docent, Department of Medicine, Solna. Project: Identifying potential biomarkers for virus-induced type 1 diabetes.
- Johan Sandberg, professor at the Department of Medicine, Huddinge. Project: Research the role of MAIT cells in liver biology and chronic hepatitis B viral infection.
- Michael Uhlin, docent at the Department of Oncology-Pathology. Project: Characterization of the immune microenvironment in early prostate cancer.